Research Analysts Issue Forecasts for Cocrystal Pharma, Inc.’s FY2024 Earnings (NASDAQ:COCP)

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a research note issued to investors on Thursday, August 15th. Noble Financial analyst R. Leboyer expects that the company will earn ($1.67) per share for the year. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.02) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q1 2025 earnings at ($0.60) EPS, Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.54) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cocrystal Pharma in a report on Tuesday, May 14th.

Cocrystal Pharma Stock Down 9.0 %

Shares of COCP stock opened at $1.91 on Monday. The company’s fifty day simple moving average is $2.20 and its two-hundred day simple moving average is $1.86. Cocrystal Pharma has a 52 week low of $1.33 and a 52 week high of $3.23. The stock has a market cap of $19.43 million, a P/E ratio of -1.10 and a beta of 1.41.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Wednesday, August 14th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02).

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.